Coming out of the 2018 International Liver Congress, some analysts think the latest data presented by Gilead Sciences Inc. pose questions about the efficacy of its lead candidate for non-alcoholic steatohepatitis (NASH), selonsertib. But other companies in the close race to bring the first NASH therapy to market, such as NGM Biopharmaceuticals Inc. and Madrigal Pharmaceuticals Inc., received more positive reception for their updates.
Selonsertib, an apoptosis-signaling kinase 1 (ASK1) inhibitor, received mixed reviews following the presentation of a proof-of-concept trial testing different combinations...